[ACX 2026] Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
AvrupaOne-OffSağlık ve TıpBilim2ayManifold MarketsKYC yokDoğrulanmış sonuçlanma verisiOrta düzey kalibreVeri kalitesi uyarısıKaynak verileri bozulmuş
25 Eki 2026 16:20 UTC itibarıyla veriler · politika pm-quality-4
Güncel topluluk tahminiHayır 90.2%
Tahminciler
29
Soru türü
binary
Yöntem
Play-money forecasting platform
Kaynak türü
Tahmin
Piyasa verileri
9 saat önce güncellendi
Guncelligini yitirmis6 Oca 26 22:51 UTC31 Ara 26 23:59 UTC
Trendler
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
When will commercial gene-editing therapy be available?
Manifold MarketsWill a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
Manifold MarketsBy 2030, will gene editing to cure serious genetic diseases be seen as generally uncontroversial?
Manifold MarketsWhere will human germline gene editing resulting in a live birth first occur legally?
Manifold MarketsThere will be more children born via artificial wombs than not in first world countries before 2050
Manifold MarketsPreimplantation genetic diagnosis liberalised in Germany before 2027?
Manifold MarketsKurallar
(https://www.metaculus.com/questions/embed/41169) Resolves according to Metaculus resolution.
- Metaculus high-level description: This question will resolve as Yes if any of the US FDA, UK MHRA, or the EU Commission authorizes the use or sale of a therapy whose primary mechanism directly editing the patient's genomic DNA for any human condition other than sickle cell disease and beta thalassemia before January 1, 2027.
